The cost of Fetzima (tolevamer) is not publicly disclosed by its manufacturer, Eidos Therapeutics, a subsidiary of BridgeBio Pharma [1]. Information regarding the exact pricing of Fetzima is typically made available to healthcare providers and payers through direct negotiations and formulary discussions [1].
How is Fetzima administered?
Fetzima is administered intravenously [1]. This method of delivery is a key factor in the overall cost of treatment, as it requires administration in a clinical setting by healthcare professionals.
What is Fetzima used to treat?
Fetzima is an investigational drug that targets transthyretin amyloidosis (ATTR), a rare and progressive disease [1]. Specifically, it is being developed to treatATTR cardiomyopathy (ATTR-CM), a form of the disease that affects the heart [1].
What is the development status of Fetzima?
Fetzima has undergone clinical trials, including the Phase 3 VITAL study, to evaluate its safety and efficacy in treating ATTR-CM [1]. BridgeBio Pharma submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Fetzima in December 2023, based on the results of this study [1]. The FDA has accepted the application and granted it Priority Review, with a target action date set for July 2024 [1].
What are the potential side effects of Fetzima?
In clinical trials, the most common adverse events reported with Fetzima were infusion-related reactions, such as headache, chills, dizziness, and fatigue [1]. Other potential side effects include nausea, diarrhea, and muscle spasms [1].
When might Fetzima be approved?
With a target action date from the FDA in July 2024, Fetzima could potentially receive approval for the treatment of ATTR-CM in the latter half of the year, pending the FDA's decision [1].
What other treatments are available for ATTR-CM?
Currently, approved treatments for ATTR-CM include tafamidis (Vyndaqel and Vyndamax) and diflunisal [2][3]. These treatments aim to stabilize the transthyretin protein and slow disease progression.
What is the mechanism of action for Fetzima?
Fetzima works by binding to the transthyretin (TTR) protein, stabilizing its tetrameric form and preventing its dissociation into monomers, which are prone to misfolding and forming amyloid fibrils [1]. This mechanism aims to reduce the accumulation of amyloid deposits in organs like the heart [1].
How does Fetzima compare to other ATTR treatments?
Fetzima's mechanism of stabilizing the TTR tetramer is similar to that of tafamidis [1]. However, clinical trial data specifically comparing Fetzima head-to-head with existing therapies like tafamidis will be crucial for understanding its comparative efficacy and safety profile once it becomes available.
What is the patent status for Fetzima?
Information on the specific patents covering Fetzima and its use can be found through patent databases and intellectual property tracking services, such as DrugPatentWatch.com [1]. These resources can provide details on patent filings, grant dates, and expiry timelines, which are critical for understanding market exclusivity and the potential for generic competition in the future.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.vyndaqel.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633818/